Lenalidomide-induced myelosuppression is associated with renal dysfunction: Adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy

British Journal of Haematology

Volumn 138, Issue 5, 2007, Pages 640-643

  Niesvizky, Ruben ^a   Naib, Tara ^a   Christos, Paul J ^a   Jayabalan, David ^a   Furst, Jessica R ^a   Jalbrzikowski, Jessica ^a   Zafar, Faiza ^a   Mark, Tomer ^a   Lent, Richard ^a   Pearse, Roger N ^a   Ely, Scott ^a   Leonard, John P ^a   Mazumdar, Madhu ^a   Chen Kiang, Selina ^a   Coleman, Morton ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Combination therapy; Dexamethasone; Lenalidomide; Myeloma; Renal insufficiency

Indexed keywords

ACETYLSALICYLIC ACID; CLARITHROMYCIN; COTRIMOXAZOLE; CREATINE; DEXAMETHASONE; LENALIDOMIDE; OMEPRAZOLE;

ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG POTENTIATION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CREATININE; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; NEUTROPENIA; RENAL INSUFFICIENCY; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 34547615365     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06698.x     Document Type: Article

References (12)

1. Anderson, K.C. (2005) Lenalidomide and thalidomide: mechanisms of action - similarities and differences. Seminars in Hematology, 42 (4 Suppl. 4 S3 S8.
2. Celgene Corporation (2007) Revlimid® (lenalidomide) 5 mg, 10 mg, 15 mg and 25 mg capsules. Available at: http://www.revlimid.com/pdf/REVLIMID_PI. pdf. Accessed on April 19, 2007.
3. Corral, L.G., Haslett, P.A., Muller, G.W., Chen, R., Wong, L., Ocampo, C.J., Patterson, R.T., Stirling, D.I. Kaplan, G. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunololgy, 163, 380 386.
4. Dimopoulos, M.A., Spencer, A., Attal, M., Prince, M., Harousseau, J-L., Dmoszynska, A., Yu, Z., Olesnyckyj, M., Zeldis, J. Knight, R. (2005) Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood (ASH Annual Meeting Abstracts), 106, 6a Abstract 6.
5. Food and Drug Administration (2006) FDA Approves Lenalidomide Oral Capsules (Revlimid) for Use in Combination with Dexamethasone in Patients with Multiple Myeloma. July 20, 2006. Available at: http://www.fda.gov/cder/Offices/ OODP/whatsnew/lenalidomide.htm. Accessed on April 19, 2007.
6. Mitsiades, C.S. Mitsiades, N. (2004) CC-5013 (Celgene). Current Opinion in Investigational Drugs, 5, 635 647.
7. Niesvizky, R., Jayabalan, D.S., Zafar, F., Christos, P., Lent, R., Pearse, R., Tepler, J., Ely, S., Shore, T., Harpel, J., Schuster, M., Pekle, K., Jalbrzikowski, J.B., Cho, H.J., Leonard, J., Mazumdar, M., Chen-Kiang, S. Coleman, M. (2006) Lenalidomide induced myelosuppression is potentially associated with renal dysfunction in treatment naïve myeloma (MM) patients receiving BiRD (Biaxin®/Revlimid®/Dexamethasone) combination therapy (Rx). Blood (ASH Annual Meeting Abstracts), 108, 1013a Abstract3549.
8. Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., Zeldenrust, S.R., Kumar, S., Greipp, P.R., Fonseca, R., Lust, J.A., Russell, S.J., Kyle, R.A., Witzig, T.E. Gertz, M.A. (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106, 4050 4053.
9. Reece, D.E., Masih-Khan, E., Chen, C., Wang, L., Dean, S., Kukreti, V., Mikhael, J.R., Trudel, S., Knight, R. Zeldis, J. (2006) Use of lenalidomide (Revlimid®) +/- corticosteroids in relapsed/refractory multiple myeloma patients with elevated baseline serum creatinine levels. Blood (ASH Annual Meeting Abstracts), 108, 1013a Abstract 3548.
10. Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063 3067.
11. Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., Schlossman, L., Rajkumar, S.V., Desikan, K.R., Hideshima, T., Munshi, N.C., Kelly-Colson, K., Doss, D., McKenney, M.L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W.S., Zeldis, J., Knight, R., Weller, E. Anderson, K.C. (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, 3458 3464.
12. Weber, D., Wang, M., Chen, C., Belch, A., Stadtmauer, E.A., Niesvisky, R., Yu, Z., Olesnyckyj, M., Zeldis, J., Knight, R.D. Dimopoulos, M. (2006) Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood (ASH Annual Meeting Abstracts), 108, 1012a Abstract 3547.